|
1
|
Adjei AA: Lung cancer worldwide. J Thorac
Oncol. 14:9562019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Goldstraw P, Ball D, Jett JR, Le Chevalier
T, Lim E, Nicholson AG and Shepherd FA: Non-small-cell lung cancer.
Lance. 378:1727–1740. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jamal-Hanjani M, Wilson GA, McGranahan N,
Brikbak N, Watkins TBK, Veeriah S, Shafi S, Johnson DH, Mitter R,
Rosenthal R, et al: Tracking the evolution of non-small-cell lung
cancer. N Engl J Med. 376:2109–2121. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chan BA and Hughes BG: Targeted therapy
for non-small cell lung cancer: Current standards and the promise
of the future. Transl Lung Cancer Res. 4:36–54. 2015.PubMed/NCBI
|
|
5
|
Janku F, Stewart DJ and Kurzrock R:
Targeted therapy in non-small-cell lung cancer-is it becoming a
reality? Nat Rev Clin Oncol. 7:401–414. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Herbst RS, Morgensztern D and Boshoff C:
The biology and management of non-small cell lung cancer. Nature.
553:446–454. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hirsch FR, Suda K, Wiens J and Bunn PA Jr:
New and emerging targeted treatments in advanced non-small-cell
lung cancer. Lancet. 388:1012–1024. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Joseph AM, Rothman AJ, Almirall D, Begnaud
A, Chiles C, Cinciripini PM, Fu SS, Graham AL, Lindgren BR, Melzer
AC, et al: Lung cancer screening and smoking cessation clinical
trials. SCALE (smoking cessation within the context of lung cancer
screening) collaboration. Am J Respir Crit Care Med. 197:172–182.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Saito S, Espinoza-Mercado F, Liu H, Sata
N, Cui X and Soukiasian HJ: Current status of research and
treatment for non-small cell lung cancer in never-smoking females.
Cancer Biol Ther. 18:359–368. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Eser PÖ and Jänne PA: TGFβ pathway
inhibition in the treatment of non-small cell lung cancer.
Pharmacol Ther. 184:112–130. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tomasini P, Walia P, Labbe C, Jao K and
Leighl NB: Targeting the KRAS pathway in non-small cell lung
cancer. Oncologist. 21:1450–1460. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhou R, Wu Y, Wang W, Su W, Liu Y, Wang Y,
Fan C, Li X, Li G, Li Y, et al: Circular RNAs (circRNAs) in cancer.
Cancer Lett. 425:134–142. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Meng S, Zhou H, Feng Z, Xu Z, Tang Y, Li P
and Wu M: CircRNA: Functions and properties of a novel potential
biomarker for cancer. Mol Cancer. 16:942017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ji F, Du R, Chen T, Zhang M, Zhu Y, Luo X
and Ding Y: Circular RNA circSLC26A4 accelerates cervical cancer
progression via miR-1287-5p/HOXA7 axis. Mol Ther Nucleic Acids.
19:413–420. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
He J: Knocking down miR-15a expression
promotes the occurrence and development and induces the EMT of
NSCLC cells in vitro. Saudi J Biol Sci. 24:1859–1865. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Detterbeck FC, Boffa DJ, Kim AW and Tanoue
LT: The eighth edition lung cancer stage classification. Chest.
151:193–203. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-timequantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Stokes WA, Bronsert MR, Meguid RA, Blum
MG, Jones BL, Koshy M, Sher DJ, Louie AV, Palma DA, Senan S, et al:
Post-treatment mortality after surgery and stereotactic body
radiotherapy for early-stage non-small-cell lung cancer. J Clin
Oncol. 36:642–651. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Goyal G, Kommalapati A, Bartley AC,
Gunderson TM, Adjei AA and Go RS: Association between hospital
volume and mortality of patients with metastatic non-small cell
lung cancer. Lung Cancer. 122:214–219. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Postmus PE, Kerr KM, Oudkerk M, Senan S,
Waller DA, Vansteenkiste J, Escriu C and Peters S; ESMO Guidelines
Committee, : Early and locally advanced non-small-cell lung cancer
(NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment
and follow-up. Ann Oncol. 28 (Suppl-4):iv1–iv21. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lan F, Yue X, Ren G, Li H, Ping L, Wang Y
and Xia T: miR-15a/16 enhances radiation sensitivity of non-small
cell lung cancer cells by targeting the TLR1/NF-κB signaling
pathway. Int J Radiat Oncol Biol Phys. 91:73–81. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bozok Çetintaş V, Tetik Vardarlı A, Düzgün
Z, Tezcanlı Kaymaz B, Açıkgöz E, Aktuğ H, Kosova Can B, Gündüz C
and Eroğlu Z: miR-15a enhances the anticancer effects of cisplatin
in the resistant non-small cell lung cancer cells. Tumour Biol.
37:1739–1751. 2016. View Article : Google Scholar
|
|
23
|
Guo S, Li M, Li J and Lv Y: Inhibition
mechanism of lung cancer cell metastasis through targeted
regulation of Smad3 by miR-15a. Oncol Lett. 19:1516–1522.
2020.PubMed/NCBI
|
|
24
|
Yang T, Thakur A, Chen T, Chen T, Yang L,
Lei G, Liang Y, Zhang S, Ren H and Chen M: MicroRNA-15a induces
cell apoptosis and inhibits metastasis by targeting BCL2L2 in
non-small cell lung cancer. Tumour Biol. 36:4357–4365. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pickering BF, Yu D and Van Dyke MW:
Nucleolin protein interacts with microprocessor complex to affect
biogenesis of microRNAs 15a and 16. J Biol Chem. 286:44095–44103.
2011. View Article : Google Scholar : PubMed/NCBI
|
